Tests empasiprubart against placebo in adults with CIDP
Tests empasiprubart, or a placebo, in adults with chronic inflammatory demyelinating polyneuropathy.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Key facts
- Where
- Córdoba and Rosario, ArgentinaSee the 3 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who still have disability and active disease.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Typical CIDP, or motor, multifocal, focal or distal CIDP, meeting the 2021 EAN/PNS guideline criteria, with residual disability and active disease.
- Earlier treatment
- People can be new to CIDP treatment, can have stopped treatment, or can be on treatment now. Those on treatment must stop it before the first study dose and be willing to switch to the study drug.
Main reasons for not taking part
- Only possible CIDP under the 2021 EAN/PNS guidelines
- Sensory CIDP, including sensory-predominant CIDP
- Polyneuropathy of other causes
- Clinical diagnosis of systemic lupus erythematosus (SLE)
- Other long-acting immunomodulatory treatment, or past total lymphoid irradiation or bone marrow transplantation
Read by machine on 10 November 2026.
Where in Argentina
- Instituto Privado KremerCórdoba, ArgentinaTaking people
- INECO Neurociencias OroñoRosario, ArgentinaTaking people
- Instituto Médico de la Fundación Estudios ClínicosRosario, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- argenx
- Trial code
- NCT07091630EU 2025-520805-10-00
- Record updated
- 9 November 2026
- Original description
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).Read full original descriptionShow less
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).
More information can be found here: https://clinicaltrials.argenx.com/emnergize
Inclusion: Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021); Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP; Has residual disability and active disease; Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors); Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP.
Exclusion: Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation; Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021); Sensory CIDP (including sensory-predominant CIDP); Polyneuropathy of other causes; Clinical diagnosis of systemic lupus erythematosus (SLE).